NYSE CRM refers to the stock symbol for Salesforce.com Inc., a cloud-based customer relationship management (CRM) software company listed on the New York Stock Exchange (NYSE). The stock symbol “CRM” represents Salesforce.com Inc. and can be used to track its performance and trading activity on the NYSE. 

Salesforce Inc. (CRM) is performing notably in the stock market. The stock was last reported at a price of $261.60 at the close of the market, with a subsequent increase in pre-market trading to $264.50, reflecting a 1.11% rise​​. The stock’s recent performance shows an opening price of $255.01 and a previous close at $257.21, moving within a day’s range of $254.51 to $262.31. Over the past year, Salesforce’s stock has fluctuated between a 52-week range of $126.34 to $263.43​​.

In terms of Salesforce’s business operations, the company is a leading provider of Customer Relationship Management (CRM) technology, offering services and solutions that bring companies and customers together globally. Their services range from sales, where they help in storing data, monitoring leads and progress, and forecasting opportunities, to customer service, enabling highly personalized service and support at scale. Additionally, Salesforce’s platform offers a flexible solution that allows companies of various types to build and develop their customer relationship strategies effectively​​.

Salesforce has a market capitalization of $253.229 billion and, according to analyst forecasts, the stock has an average rating of “Buy.” The 12-month stock price forecast is set at $255.57, indicating a slight decrease of -2.31% from the latest price​​. This forecast provides a perspective on market expectations and investor sentiment towards the company.

For investors or individuals interested in Salesforce’s stock performance, these figures offer a snapshot of the company’s current standing in the market. However, it’s always recommended to stay updated with the latest financial news and perform thorough research before making any investment decisions.